Similar studies have been conducted in other immunological diseases; in rheumatoid arthritis, ADA treatment resulted in reductions in plasma levels of chemerin, correlated with decreases in IL-6 and macrophage migration inhibitory factor concentrations [29]. The gene discussed is RARRES2; the disease is rheumatoid arthritis.